A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 615
- Registration Number
- NCT01009086
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 228
- Registration Number
- NCT01009047
PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region
Phase 4
Completed
- Conditions
- PneumoniaPneumonia, Ventilator-AssociatedUrinary Tract Infections
- Interventions
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00986102
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1452
- Registration Number
- NCT00968812
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain
Phase 2
Completed
- Conditions
- Pain, MigratoryPain, RadiatingPain, BurningPain, SplittingPain, Crushing
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00929188
First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- InflammationRheumatoid Arthritis
- Interventions
- Drug: NNC0142-0002Drug: placebo
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 65
- Registration Number
- NCT00927927
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT00924469
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Siltuximab11 mg/kg
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 118
- Registration Number
- NCT00911859
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT00910754
- Locations
- 🇨🇦
BC Cancer Agency-Vancouver, Vancouver, British Columbia, Canada
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 3
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1088
- Registration Number
- NCT00887198
© Copyright 2025. All Rights Reserved by MedPath